Emerging Therapeutic Targets and Therapies in Idiopathic Pulmonary Fibrosis

Parvathaneni, Vineela; Shukla, Snehal K.; Gupta, Vivek

doi:10.1007/978-3-319-98143-7_8

Cited by 1 publication

(2 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epithelial cells turn into cell types with mesenchymal properties, thus modifying their shape, increasing their motility, and leading to the emergence of mesenchymal markers, e.g., N-cadherin (CDH2), vimentin, and α-SMA [ 134 ]. This transition of epithelial cells to mesenchymal properties leads to the progression of myofibroblast formation and is thus another key player in IPF pathogenesis [ 135 ]. Wnt signaling is crucial in pulmonary fibrosis as research data show that applying Wnt1-inducible signaling pathway protein-1 neutralizing antibodies to BLM-treated mice attenuates the progression of IPF [ 136 ].…”

Section: Potential Therapeutic Targets Of Pfmentioning

confidence: 99%

See 1 more Smart Citation

Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis

Hasan

Paul

et al. 2022

Molecules

View full text Add to dashboard Cite

Pulmonary fibrosis (PF) is a disease-refractive lung condition with an increased rate of mortality. The potential factors causing PF include viral infections, radiation exposure, and toxic airborne chemicals. Idiopathic PF (IPF) is related to pneumonia affecting the elderly and is characterized by recurring scar formation in the lungs. An impaired wound healing process, defined by the dysregulated aggregation of extracellular matrix components, triggers fibrotic scar formation in the lungs. The potential pathogenesis includes oxidative stress, altered cell signaling, inflammation, etc. Nintedanib and pirfenidone have been approved with a conditional endorsement for the management of IPF. In addition, natural product-based treatment strategies have shown promising results in treating PF. In this study, we reviewed the recently published literature and discussed the potential uses of natural products, classified into three types—isolated active compounds, crude extracts of plants, and traditional medicine, consisting of mixtures of different plant products—in treating PF. These natural products are promising in the treatment of PF via inhibiting inflammation, oxidative stress, and endothelial mesenchymal transition, as well as affecting TGF-β-mediated cell signaling, etc. Based on the current review, we have revealed the signaling mechanisms of PF pathogenesis and the potential opportunities offered by natural product-based medicine in treating PF.

show abstract

Section: Potential Therapeutic Targets Of Pfmentioning

confidence: 99%

“…Dysregulation of MMPs stimulates fibroblast proliferation and extends the event of ECM accumulation and consequently becomes an essential inducer of pulmonary fibrosis development [ 134 ]. MMP inhibition could be a retrospective target for the disease management of IPF [ 135 ].…”

Section: Potential Therapeutic Targets Of Pfmentioning

confidence: 99%

Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis

Hasan

Paul

et al. 2022

Molecules

View full text Add to dashboard Cite

show abstract

Emerging Therapeutic Targets and Therapies in Idiopathic Pulmonary Fibrosis

Cited by 1 publication

References 159 publications

Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis

Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis

Contact Info

Product

Resources

About